Labeled Estrogen Receptor Imaging Agent ¹⁸F-FES And Tracer Kinetics

Breast cancer is one of the most common malignant tumors in women.Although the diagnosis and treatment of breast cancer has been greatly developed in recently years,it is still a serious health problem in today's society.Traditional methods of breast cancer screening and diagnosis are structural imaging,but molecular imaging becomes more and more important in the diagnosis of breast cancer.With the application of various new types of radionuclide imaging agents in clinical examinations,the development of radioactive tracers to adapt to the biological characteristics of tumor will be more helpful to make treatment plans and carry out personalized treatment.At the same time,the study on the specific target of breast cancer targeted therapy based on the original metabolic imaging will make more and more imaging agents to accept,so as to provide a better basis for early diagnosis of breast cancer,improve the efficacy and guide clinical treatment.The uptake of 18 F labeled ER?estradiol?was related to the ER density of the tumor.First this research is in the early breast cancer with 18F-FDG imaging based on by nucleophilic substitution method synthesis and labeled estrogen analogues ¹⁸F-FES(16-18F-17 beta altered ¹⁸F-FES)as estrogen receptor imaging agent.ER expression levels of breast cancer cell lines were observed in vitro to observe the expression level of different breast cancer cell lines?ER positive MCF-7 breast cancer cells and ER expression negative MDA-MB-231?¹⁸F-FES uptake and its regulation,on the basis of ER antagonist tamoxifen blocking experiments,from two aspects of ER and ¹⁸F-FES binding specificity,as well as ¹⁸F-FES cell uptake and ER expression.To observe the distribution of ¹⁸F-FES in different breast cancer patients,and to provide a scientific basis for the specific diagnosis and treatment of breast cancer,the ¹⁸F-FES provides the basis and guidance for the clinical treatment of breast cancer patients with personalized endocrine therapy and evaluation of its efficacy.In this study,we aim to provide the basis for the PET ¹⁸F-FES receptor imaging for the determination and monitoring of ER expression in breast cancer and to provide a basis for clinical application.